SCHEMBL30142919

SCHEMBL30142919

COc1c(N)cccc1-c1cnn(CCNC(=O)OC(C)(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.43
DRD2 P14416 5/20 0.41
MALT1 Q9UDY8 1/20 0.39
PDPK1 O15530 1/20 0.38
CCNB2 O95067 1/20 0.38
PRKCB P05771 1/20 0.38
CDK1 P06493 1/20 0.38
LYN P07948 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
GSK3B P49841 1/20 0.38
RPS6KA3 P51812 1/20 0.38
CCNA1 P78396 1/20 0.38
CCNB3 Q8WWL7 1/20 0.38
SCN9A Q15858 1/20 0.38
TYK2 P29597 1/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
ALOX5AP P20292 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24950644 0.86 PDK2 (0.41) PDK2LYNGSK3BTYK2BTK
SCHEMBL15936752 0.82 PDK2 (0.46) PDK2DRD2MALT1SCN9AACACB
SCHEMBL30839066 0.81 DRD2 (0.40) DRD2MALT1PDPK1CCNB2PRKCB
SCHEMBL28602394 0.77 LCK (0.39) PDK2TYK2FEN1BTK
SCHEMBL13740008 0.77 ALDH1A1 (0.41) DRD2MALT1JAK3BTK
SCHEMBL31436646 0.76 SUV39H2 (0.41) PDK2DRD2MALT1PDPK1CCNB2
SCHEMBL30606133 0.76 SUV39H2 (0.41) PDK2DRD2MALT1PDPK1CCNB2
SCHEMBL29828607 0.76 DRD2 (0.45) DRD2MALT1
SCHEMBL9977832 0.76 CREBBP (0.42) PDK2DRD2MALT1GSK3BSCN9A
SCHEMBL31627121 0.74 DRD2 (0.44) PDK2DRD2MALT1PDPK1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240840-B2 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-04 US disclosed
US-20230020273-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA BRISTOL MYERS SQUIBB CO (US) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020273-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA TYK2, IFNG, JAK3 PDK2 724/4885DRD2 3214/4885MALT1 1219/4885
US-12240840-B2 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha TYK2, IFNG, JAK3 PDK2 724/4885DRD2 3214/4885MALT1 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.